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Although cancer immunotherapy has achieved significant breakthroughs in recent 
years, its overall efficacy remains limited in the majority of patients. One major barrier is 
exhaustion of tumor antigen-specific CD8+ tumor-infiltrating lymphocytes (TILs), which 
conventionally has been attributed to persistent stimulation with antigen within the 
tumor microenvironment (TME). A series of recent studies have highlighted that the TME 
poses significant metabolic challenges to TILs, which may contribute to their functional 
exhaustion. Hypoxia increases the expression of coinhibitors on activated CD8+ T cells, 
which in general reduces the T cells’ effector functions. It also impairs the cells’ ability 
to gain energy through oxidative phosphorylation. Glucose limitation increases the 
expression of programed cell death protein-1 and reduces functions of activated CD8+ 
T cells. A combination of hypoxia and hypoglycemia, as is common in solid tumors, 
places CD8+ TILs at dual metabolic jeopardy by affecting both major pathways of energy 
production. Recently, a number of studies addressed the effects of metabolic stress 
on modulating CD8+ T cell metabolism, differentiation, and functions. Here, we discuss 
recent findings on how different types of metabolic stress within the TME shape the 
tumor-killing capacity of CD8+ T cells. We propose that manipulating the metabolism of 
TILs to more efficiently utilize nutrients, especially during intermittent periods of hypoxia 
could maximize their performance, prolong their survival and improve the efficacy of 
active cancer immunotherapy.
Keywords: lack of glucose, hypoxia, cD8+ t cell metabolism, metabolic stress, tumor-infiltrating lymphocytes, 
tumor microenvironment, fatty acid metabolism, ketone bodies
iNtrODUctiON
Following antigenic stimulation, differentiation of naive CD8+ T cells into effector cells is accompanied 
by metabolic reprograming to accommodate their increased demand for energy and biomass forma-
tion. Resting CD8+ T cells primarily gain energy through oxidative phosphorylation (OXPHOS), the 
mitochondrial pathway of energy production (1). The tricarboxylic acid (TCA) cycle, which is linked 
to OXPHOS, oxidizes acetyl-CoA. This metabolite can be derived from carbohydrates, amino acids, 
or FAs. Upon CD8+ T cell activation, T cell receptor (TCR) and costimulator CD28 ligation activate 
the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin 
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(mTOR) pathways, which in turn increase the activity of hypoxia-
inducible factor (HIF)-1α and Myc (2). HIF-1α augments surface 
expression of Glut1, and thereby allows for increased uptake of 
glucose. Akt and Myc increase the activity of several glycolytic 
enzymes, whereas PI3K activation reduces expression of enzymes 
of the TCA cycle and OXPHOS (3–5). All of these signals drive 
CD8+ T cells to rely increasingly on glycolysis after activation 
(6). Glycolysis is less efficient but faster in generating ATP and 
provides building blocks to support cell proliferation and effector 
functions.
Once T cells are past the acute activation phase, they resume 
energy production through the TCA cycle and OXPHOS, which 
is partially supported by fatty acid oxidation (FAO) (7, 8). One 
facilitator of this metabolic switch is increased expression of 
PD-1, a coinhibitor that blocks CD28-mediated activation of the 
mTOR pathway (9) and reduces glycolysis and promotes lipid 
metabolism (10). PD-1 thereby prevents overwhelming CD8+ T 
cell activities and promotes memory formation (11).
Increased expression of PD-1 also identifies the so-called 
exhausted CD8+ T cells, which evolve during chronic infections 
due to continuous antigen-driven stimulation (12). Exhausted 
CD8+ T cells show progressive increases in the expression of addi-
tional coinhibitors, such as lymphocyte-activation gene 3 (LAG-
3), CD160, 2B4, and others, which combined with loss of effector 
functions eventually lead to cell death (13). Within the tumor 
microenvironment (TME), CD8+ T cells become exhausted (14). 
It is assumed that lack of an effective antitumor T cell response 
is at least in part linked to exhaustion. Consequently, blockade of 
coinhibitor pathways by antibodies such as to anti-PD-1 or anti-
PD-L1 has yielded promising results in some cancer patients (15).
The etiology of T cell exhaustion within the TME warrants 
further discussion. High level of antigen as found during chronic 
viral infections may not be solely responsible. The amount of anti-
gens within a tumor would not be expected to be overwhelming, 
especially as tumor cells commonly downregulate MHC class I 
expression (16), which makes their antigens virtually invisible to 
CD8+ T cells. Instead, we propose that CD8+ T cell exhaustion 
may be triggered by metabolic stress within the TME. Cancer cells 
ferociously consume glucose to fuel energy production through 
glycolysis, which can lead to hypoglycemia within tumors. In 
addition, angiogenesis often lags behind expansion of solid 
tumors, leading to hypoxia in some areas of the TME. T cells that 
infiltrate solid tumors thus face dual metabolic jeopardy; lack of 
glucose prohibits energy production through glycolysis, whereas 
lack of O2 prevents energy production through OXPHOS. How 
tumor-specific CD8+ tumor-infiltrating lymphocytes (TILs) 
cope with these challenges and how metabolic reprograming 
of CD8+ TILs will affect their antitumor performance require 
further investigations, in order to improve the efficacy of cancer 
immunotherapy.
eFFects OF HYPOXiA ON cD8+ tiL 
MetABOLisM AND FUNctiONs
Solid tumors commonly have areas of hypoxia. This can be 
caused by lack of perfusion due to structural and functional 
abnormalities of the tumor microvasculature, general anemia of 
the patient, or insufficient diffusion due to lack of angiogenesis. 
The latter affects cells once they are more than 70 μm away from 
a blood vessel. Studies have shown that up to 50–60% of solid 
tumors of a variety of different types possess unevenly distributed 
areas of hypoxia (17).
Tumor-infiltrating CD8+ T cells are initially activated under 
physiological O2 tension in peripheral lymphatic tissues. Upon 
tumor entry, CD8+ T cells will be subjected to increasingly severe 
hypoxia once they leave areas close to blood vessels; this will 
activate HIF-1α. HIF-1α signaling adjusts the cells’ metabolism 
to allow for energy production when O2 is limiting. HIF-1α 
enhances glycolysis by CD8+ T cells mainly by promoting the 
activity of lactate dehydrogenase A (LDHa), while inhibits 
OXHPOS by increasing expression of pyruvate dehydrogenase 
kinase 1 (PDK1), which prevents the oxidation of pyruvate to 
acetyl-CoA (18, 19). CD8+ TILs under hypoxia therefore must 
increase glucose consumption to fuel glycolysis.
A series of in vitro and in vivo studies in the past two decades 
show that hypoxia dampens lymphocyte activation, diminishes 
their proliferation, and reduces the ability of activated T cells 
to produce cytokines or lytic enzymes (20–24). T cell activa-
tion causes release of Ca2+ from intracellular stores followed by 
sustained Ca2+ influx, which is inhibited by increased HIF-1α 
activity (25). Whole body hypoxia dampens inflammation and 
T cell functions in mice and humans (26, 27). These data show 
that hypoxia is immunosuppressive and metabolic reprograming 
due to increased activity of HIF-1α may contribute to reductions 
of immune responses. This could be caused by reduced ATP pro-
duction due to impaired OXPHOS under hypoxia. Additionally, 
hypoxia is known to increase accumulation of reactive oxygen 
species (ROS), which may induce apoptosis of activated T cells 
(28, 29). Vice versa, activated CD8+ T cells with a partial deficiency 
in HIF-1α show enhanced production of cytokines (30, 31). One 
study has shown that under hypoxia or with increased HIF-1α 
activity T cells increase expression of coinhibitors, including 
CTLA-4, CD244, and LAG-3, and decrease levels of T-bet (32), 
a key transcription factor that controls many of the T cells’ func-
tions, again indicating that hypoxia is immunosuppressive.
Conversely, two recent reports show that hypoxia and increases 
in HIF-1α activity promote effector T cell functions, especially 
production of the lytic enzymes granzyme B and perforin 
(32, 33). There is a caveat with these studies; both used a protocol 
in which after an initial 48  h of activation, CD8+ T cells were 
rested for several days in IL-2-supplemented medium before 
being subjected to hypoxia. Unlike highly activated CD8+ T cells, 
resting CD8+ T cells rely more on FAO and OXPHOS for energy 
production. This metabolic reprograming and their decreased 
energy demand may allow CD8+ T cells to improve some func-
tions upon hypoxia. In real life CD8+ T cells induced by a cancer 
vaccine or tumor antigens (TAs) that leaked into lymphatic tis-
sues are unlikely to rest before they infiltrate a tumor, where they 
may receive additional activation signals. Results obtained with 
resting cells are thus not pertinent to TILs exposed to hypoxia. 
The same papers showed that genetic depletion of HIF-1α reduces 
CD8+ T cell functions while its constitutive overexpression 
through functional depletion of the Von Hippel–Lindau (VHL) 
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factor improves functions. During the initial phase of T cell 
activation, HIF-1α is essential to allow T cells to use glycolysis. 
The effects of its complete absence or increased expression during 
this critical phase of differentiation may differ from changes in 
HIF-1α activity during later phases of activation. These studies 
thus give limited insights into the effect of hypoxia or HIF-1α on 
CD8+ TILs, which encounter limited O2 after activation in the 
periphery once they penetrate into the tumor.
Hypoxia and increased HIF-1α activity in tumor tissues in 
general correlate with poor prognosis of cancer patients (34, 35). 
Hypoxia not only affects protective immune responses but also 
promotes tumorigenesis by enhancing proliferation of cancer 
cells and increasing their PD-L1 surface expression (36). The 
latter in turn may further dampen functions and survival of 
PD-1+ TILs. Hypoxia may also increase the suppressive activity of 
tumor-infiltrating myeloid suppressor cells and tumor-associated 
macrophages, which will lead to further impairments of CD8+ 
TIL functions (37, 38). Overall, all of these studies strongly sug-
gest that lack of O2 negatively affects metabolism and functions 
of CD8+ TILs.
eFFects OF HYPOGLYceMiA ON 
MetABOLisM AND FUNctiONs OF tiLs
Glucose is crucial during the initial stages of CD8+ T cell activa-
tion. Naive CD8+ T cells can differentiate into effectors in absence 
of glucose but then become functionally impaired (39). Lack of 
glucose also dampens effector functions of fully activated CD8+ 
T cells both in vitro and in vivo (39–44).
Attracted by chemokines, activated CD8+ T cells regardless 
of their antigen specificity infiltrate solid tumors. Here, they 
encounter an environment where key nutrients such as glucose 
may be limiting due to its consumption by tumor cells (45). 
Although activated CD8+ T cells express increased levels of the 
glucose transporter Glut1, in vitro studies show that their effort 
to take up glucose is thwarted by tumor cells, which are simply 
more effective at consuming this key nutrient (39). CD8+ T cell 
glycolysis within TME may further be reduced by accumulating 
concentrations of tumor cell-derived lactate, which prevents the 
monocarboxylate transporter-1-mediated, gradient-dependent 
export of lactate from CD8+ T cells. Increasing concentration of 
lactate within CD8+ T cells in turn causes a fall in pH, which 
inhibits the activity of phosphofructokinase, a key enzyme of 
glycolysis (46). In addition, glucose deprivation increases coin-
hibitor PD-1 expression on activated CD8+ T cells (47), which can 
further reduce glycolysis but enhance FA metabolism. Blockade 
of PD-1 has been shown to lessen the CD8+ TILs’ metabolic stress 
by augmenting their glycolytic capacity through increased mTOR 
signaling (39).
It has been reported that FAO can maintain the survival of 
cancer cells when glucose is not available (48). T cells may 
also be able to cope with lack of glucose by enhancing other 
metabolic pathways. Sudden deprivation of glucose can lead to 
drops in ATP with enhanced AMP in activated CD8+ T cells. 
The increased AMP:ATP ratio activates the energy sensor AMP-
activated protein kinase (AMPK). AMPK is a key regulator that 
reduces the T cells’ energy expenditure by blocking production of 
cytokines (49). Furthermore, AMPK maintains T cell viability by 
decreasing glycolysis and anabolic processes through inhibition 
of the mTOR pathway, while enhancing OXPHOS fueled by FAs 
and glutamine (50, 51). In agreement, the studies showed that 
knockout of AMPK increases apoptosis of T cells activated with 
limited access to glucose (49).
To what degree CD8+ TILs’ functions are impaired by lack 
of glucose within the TME may depend on the T cells’ differen-
tiation status, or, in other words, on their metabolic programing 
prior to enter the tumors. Recently activated CD8+ effector T cells 
conditioned to use glycolysis are likely most susceptible to sudden 
loss of exogenous glucose (52, 53), as compensatory endogenous 
production of glucose through gluconeogenesis or glycogen 
degradation are not sustainable (54). By contrast, CD8+ T cells 
programed to use other nutrients may cope better with restricted 
glucose access (55). This in turn invites the testing of metabolic 
drugs that reprogram T cell metabolism as adjuvant treatments 
for active cancer immunotherapy or adoptively transferred 
TA-specific T cells.
eFFect OF HYPOXiA cOMBiNeD WitH 
HYPOGLYceMiA ON cD8+ tiL 
FUNctiONs AND MetABOLisM
Hypoxia inhibits OXPHOS but allows cells to gain energy through 
glycolysis. On the other hand, hypoglycemia reduces glycolysis 
but cells can switch to OXPHOS by burning other nutrients. 
The problem is that many tumors have low levels of glucose 
combined with areas of hypoxia, which foils both pathways of 
energy production.
Malignant cancer cells increase lipogenesis, lipolysis, FA 
secretion, and recruit adipose progenitors to the TME (56–58). 
In addition, dying tumor cells may release FAs. FAs provide ample 
energy through peroxisomal or mitochondrial FAO, which may 
be used by CD8+ TILs. FAO is preferred by some effector T cells 
such as those participating in graft versus host disease (59), 
suggesting that FAO may be preferred by T cells that encounter 
large quantities of antigens (60). Energy production through FAs 
requires more O2 than energy production through glucose to 
generate equivalent amounts of ATP. OXPHOS fueled by glucose 
yields 36 molecules of ATP and consumes 6 molecules of O2. By 
contrast, OXPHOS fueled by palmitate, a 16-carbon FA, results 
in a net yield of 129 ATP and requires 31 molecules of O2. FAs 
thus require 1.44 times more O2 than glucose to provide the same 
amount of energy, which makes it an inefficient fuel within an 
O2-deprived TME.
Ketone bodies, i.e., acetoacetate, acetone, and 
β-hydroxybutyrate, are produced during FA catabolism when 
the amount of acetyl-CoA produced by FAO overwhelms the 
processing capacity of the TCA cycle. When acetyl-CoA declines, 
ketone bodies can be converted back to acetyl-CoA providing 
a ready source of energy that requires less O2 than catabolism 
of FAs (61). Previous studies showed that under conditions of 
hypoxia and hypoglycemia, cells of the nervous system maintain 
their energy balance through the use of ketone bodies (62). We 
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propose that CD8+ TILs may do the same. T cells may take up 
ketone bodies from the surrounding or they could synthesize 
them directly (61, 63, 64).
CD8+ TILs are not stationary; they migrate throughout the 
TME (65) and we assume that their environment changes accord-
ingly. When T cells are close to vessels and O2 is readily available, 
FAs may fuel the TCA cycle and excess FA-derived acetyl-CoA 
can be converted into ketone bodies. When T cells penetrate 
deeply into the tumor and O2 becomes scarce, T cells may burn 
ketone bodies to sustain their energy requirement. As has been 
shown during heart ischemia, lack of O2 results in increases in 
AMPK, which decreases the activity of acetyl-CoA carboxylase 
(ACC) that converts acetyl-CoA to malonyl-CoA. Once cells 
have access to O2, such upon reperfusion of an ischemic heart or 
migration of TILs to areas close to vasculature, lack of malonyl-
CoA will cause a surge in FAO (66). Lipid metabolism has been 
shown to correlate with long-term survival in many different cell 
types (67, 68). It has been suggested that PD-1 ligation, which 
prevents terminal differentiation of effector CD8+ T cells (69), 
promotes survival by enhancing the cells’ FA metabolism (10). 
Ketone body metabolism also promotes metabolic fitness and 
longevity of cells by regulating histone deacetylase (HDAC) 
activities (61). Catabolism of these carbon sources may allow T 
cells to survive under hypoglycemia and intermittent hypoxia.
eXPLOriNG MetABOLic 
MANiPULAtiONs tO iMPrOve  
t ceLL-MeDiAteD iMMUNOtHerAPY  
OF cANcer
Adoptive transfer of ex vivo expanded TILs has achieved some 
successes in treatment of melanomas (70). Alternatively, T cells 
from peripheral blood can be modified to express chimeric 
antigen receptors (CARs) that recognize cell surface expressed 
TAs independent of major histocompatibility antigens (71). 
Transfer of such CAR-T cells has been remarkably successful in 
treatment of acute lymphatic leukemia or B cell lymphoma but 
in general yielded disappointing results in patients with solid 
tumors (72–76). This has been blamed on the immunosup-
pressive nature of the TME (77, 78). Treatments that reduce 
numbers or functions of regulatory T cells, myeloid suppressor 
cells, tumor-associated macrophages, or that block immune 
checkpoints have improved the efficacy of adoptive cell transfer 
for cancer therapy (79, 80).
As already mentioned, the metabolic profile of CD8+ T cells 
prior to their tumor infiltration has significant impacts on their 
longevity and performance within TME. In addition, the meta-
bolic profiles of the tumor cells will influence what nutrients are 
available to T cells. Some studies show that drugs, which inhibit 
glycolysis by tumor cells such as Glut1 inhibitors, cause tumor 
regression and increase glucose supply within the TME (81, 
82). Its use prior to cell transfer could increase the efficacy of 
cell immunotherapy. Others have shown that reducing glucose 
consumption by tumor cells through blockade of PD-L1 signaling 
allows for increased glycolytic energy production by CD8+ TILs, 
which is accompanied by improvements of their functions (39). 
A recent study shows that glucose limitation leads to reduction of 
the glycolysis metabolite phosphoenoylpruvate (PEP), which is 
essential for Ca2+-NFAT signaling in CD8+ TILs. Overexpressing 
phosphoenolpyruvate carboxykinase (PCK) 1, which converts 
the TCA cycle intermediate oxaloacetate to PEP, was shown to 
improve NFAT signaling and function of TILs (44).
However, glycolysis may accelerate terminal differentiation of 
CD8+ T cells, and thereby shorten T cell survival (83); thereby, 
limiting glycolysis by CD8+ TILs may yield better therapeutic 
effects. One study showed that inhibition of glycolysis by 
2-deoxyglucose during in vitro expansion of TA-specific CD8+ T 
cells increases their efficacy in a mouse melanoma model (52). A 
similar effect was seen when TILs were treated prior to adoptive 
transfer with an Akt inhibitor, which reduces their use of gly-
colysis and increases OXPHOS (57). Along the same line, when 
CD8+ T cells were cultured in  vitro with IL-7 or IL-15, which 
drives their differentiation toward memory, their antitumor 
efficacies in vivo significantly improved (84–86). Further studies 
showed that adoptive transfer of central memory CD8+ T cells 
confers better eradication of solid tumor masses than transfer of 
equal numbers of effector CD8+ T cells (87, 88), which led the 
authors to conclude that the T cell differentiation status, which 
dictates potential for proliferation, is crucial to ensure optimal 
efficacy of adoptive T cell transfer. We think that the metabolic 
reprograming toward preferential use of FAO and OXPHOS as 
naturally occurs during differentiation from effector to memory 
cells, may allow for the superior performance of the transferred 
T cells within TME.
cONcLUsiON
Immunotherapy of cancer is still in its infancy. T cells are able 
to stop an infection by rapidly killing millions of infected cells 
but they clearly need additional help to eliminate tumors. In 
recent years, exciting new studies have started to illuminate the 
metabolism of T cells under different conditions and its impact 
on T differentiation and functions. A better understanding of 
the metabolic programs utilized by CD8+ TILs and how they 
affect the TILs’ antitumor performance is crucial to find new 
therapeutic targets for cancer immunotherapy. Metabolic 
manipulations that could prepare TA-specific T cells, which are 
either induced by cancer vaccines or expanded ex vivo in form 
of TILs or CAR-T cells, to optimally cope with the metabolic 
constrains within the TME may significantly improve the 
overall antitumor efficacy. Undoubtedly, the type of cancer and 
peculiarities of its TME will dictate the most suited metabolic 
treatment.
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